[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07486960":3,"trial-entities:NCT07486960":596,"trial-summary:NCT07486960":599},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":44,"secondary_outcomes":49,"sex":67,"minimum_age":68,"maximum_age":69,"healthy_volunteers":70,"eligibility_criteria":71,"std_ages":83,"locations":86,"central_contacts":582,"overall_officials":587,"references":591,"see_also_links":592},"NCT07486960","7240-015","Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.","RECRUITING","2030-01-11","2026-08","2026-08-10","2026-04-20","Merck Sharp & Dohme LLC","INDUSTRY",true,"Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA.\n\nIn this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.","This study consists of a 16-week Placebo-controlled Period and a 112-week Long-term Extension (LTE), which is composed of a 40-week Main Extension and a 72-week Optional Extension.",[19],"Psoriatic Arthritis",[],"INTERVENTIONAL","TREATMENT",[24],"PHASE2",{"count":26,"type":27},140,"ESTIMATED",[29,40],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":37},"DRUG","Tulisokibart","Subcutaneous administration",[34,35,36],"High-Dose Regimen","Low-Dose Regimen","Medium-Dose Regimen",[38,39],"MK-7240","PRA023",{"type":30,"name":41,"description":32,"armGroupLabels":42},"Placebo",[43],"Placebo Regimen",[45],{"measure":46,"description":47,"timeFrame":48},"Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 16","ACR20 response is defined as a ≥20% improvement in a) tender joint count based on 68 joints and swollen joint count based on 66 joints (0= absent; 1= present) and b) ≥20% improvement in ≥3 of 5 components: i) Health Assessment Questionnaire Disability Index (HAQ-DI) (0=without any difficulty; 3= unable to do; a higher score=worse disability); ii) Physician Global Assessment of Disease Activity (PGA) (0= not active to 10= very active; a higher score= more active disease); iii) Patient's Global Assessment of Disease Activity (PtGA) (0= not active to 10= very active; a higher score= more active disease); iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain; a higher score = more pain); v) High-sensitivity C-reactive protein (hsCRP) blood values (lower value indicates less inflammation).","Week 16",[50,53,56,60,64],{"measure":51,"description":52,"timeFrame":48},"Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 16","ACR50 response is defined as a ≥50% improvement in a) tender joint count based on 68 joints and swollen joint count based on 66 joints (0= absent; 1= present) and b) ≥50% improvement in ≥3 of 5 components: i) HAQ-DI (0=without any difficulty; 3= unable to do; a higher score=worse disability); ii) PGA (0= not active to 10= very active; a higher score= more active disease); iii) PtGA (0= not active to 10= very active; a higher score= more active disease); iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain; a higher score = more pain); v) hsCRP blood values (lower value indicates less inflammation).",{"measure":54,"description":55,"timeFrame":48},"Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 16","ACR70 response is defined as a ≥70% improvement in a) tender joint count based on 68 joints and swollen joint count based on 66 joints (0= absent; 1= present) and b) ≥70% improvement in ≥3 of 5 components: i) HAQ-DI (0=without any difficulty; 3= unable to do; a higher score=worse disability); ii) PGA (0= not active to 10= very active; a higher score= more active disease); iii) PtGA (0= not active to 10= very active; a higher score= more active disease); iv) Patient assessment of Pain Severity (0= no pain to 10= most severe pain; a higher score = more pain); v) hsCRP blood values (lower value indicates less inflammation).",{"measure":57,"description":58,"timeFrame":59},"Change from Baseline in HAQ-DI Score at Week 16","The HAQ-DI is a 20-item questionnaire that measures physical function. The questionnaire assesses the degree of difficulty a person has in accomplishing tasks in 8 functional area domains (dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area domain are scored from 0 to 3 (0= without any difficulty; 3= unable to do), with a higher score indicating inability to perform activity. The overall disability score (HAQ-DI) is a summation of the highest score from each domain divided by the number of domains completed and ranges from 0 to 3, with the higher value indicating worse disability.","Baseline and Week 16",{"measure":61,"description":62,"timeFrame":63},"Number of Participants with ≥1 Adverse Event","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.","Up to approximately Week 142",{"measure":65,"description":62,"timeFrame":66},"Number of Participants Who Discontinue Study Intervention Due to an AE","Up to approximately Week 128","ALL","18 Years","80 Years",false,{"inclusion":72,"exclusion":76,"raw_text":82},[73,74,75],"Has a clinical diagnosis of PsA and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening, with symptom onset ≥6 months before Screening.","Has a diagnosis of active plaque psoriasis or documented history of plaque psoriasis.","Has history of biologic disease-modifying antirheumatic drug (bDMARD)-naïve or bDMARD-inadequate response\u002Fintolerant.",[77,78,79,80,81],"Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than PsA (such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, myositis, etc), or any other conditions that may, in the judgment of the investigator, interfere with the assessment of PsA.","Has a skin condition diagnosis, other than psoriasis that may, in the judgment of the investigator, interfere with the assessment of psoriasis.","Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \\\u003C5 years before Randomization.","Has any active infection.","Has known allergies, hypersensitivity, or intolerance to tulisokibart of its excipients.","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a clinical diagnosis of PsA and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening, with symptom onset ≥6 months before Screening.\n* Has a diagnosis of active plaque psoriasis or documented history of plaque psoriasis.\n* Has history of biologic disease-modifying antirheumatic drug (bDMARD)-naïve or bDMARD-inadequate response\u002Fintolerant.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than PsA (such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, myositis, etc), or any other conditions that may, in the judgment of the investigator, interfere with the assessment of PsA.\n* Has a skin condition diagnosis, other than psoriasis that may, in the judgment of the investigator, interfere with the assessment of psoriasis.\n* Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \\\u003C5 years before Randomization.\n* Has any active infection.\n* Has known allergies, hypersensitivity, or intolerance to tulisokibart of its excipients.",[84,85],"ADULT","OLDER_ADULT",[87,101,110,121,131,141,152,162,173,184,194,205,216,227,238,249,259,270,281,293,303,315,322,329,336,343,349,361,369,380,392,403,413,423,435,442,452,460,471,478,490,500,509,519,528,539,546,557,568,575],{"facility":88,"status":8,"city":89,"state":90,"zip":91,"country":92,"contacts":93,"geoPoint":98},"Arizona Arthritis & Rheumatology Associates, P.C. ( Site 5117)","Sun City","Arizona","85351","United States",[94],{"name":95,"role":96,"phone":97},"Study Coordinator","CONTACT","480-443-8400",{"lat":99,"lon":100},33.59754,-112.27182,{"facility":102,"status":8,"city":103,"state":90,"zip":104,"country":92,"contacts":105,"geoPoint":107},"Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 5120)","Tucson","85704-1140",[106],{"name":95,"role":96,"phone":97},{"lat":108,"lon":109},32.22174,-110.92648,{"facility":111,"status":8,"city":112,"state":113,"zip":114,"country":92,"contacts":115,"geoPoint":118},"Medvin Clinical Research - Riverside ( Site 5115)","Riverside","California","92508",[116],{"name":95,"role":96,"phone":117},"951-924-6500",{"lat":119,"lon":120},33.95335,-117.39616,{"facility":122,"status":8,"city":123,"state":113,"zip":124,"country":92,"contacts":125,"geoPoint":128},"Cohen Medical Centers ( Site 5111)","Thousand Oaks","91360",[126],{"name":95,"role":96,"phone":127},"877-972-7576",{"lat":129,"lon":130},34.17056,-118.83759,{"facility":132,"status":8,"city":133,"state":113,"zip":134,"country":92,"contacts":135,"geoPoint":138},"Medvin Clinical Research - Tujunga ( Site 5113)","Tujunga","91042",[136],{"name":95,"role":96,"phone":137},"213-281-5146",{"lat":139,"lon":140},34.25223,-118.28841,{"facility":142,"status":8,"city":143,"state":144,"zip":145,"country":92,"contacts":146,"geoPoint":149},"Arthritis and Rheumatic Disease Specialties ( Site 5105)","Aventura","Florida","33180",[147],{"name":95,"role":96,"phone":148},"305-652-6676",{"lat":150,"lon":151},25.95648,-80.13921,{"facility":153,"status":8,"city":154,"state":144,"zip":155,"country":92,"contacts":156,"geoPoint":159},"International Center for Research ( Site 5124)","Tampa","33618",[157],{"name":95,"role":96,"phone":158},"813-392-1103",{"lat":160,"lon":161},27.94752,-82.45843,{"facility":163,"status":8,"city":164,"state":165,"zip":166,"country":92,"contacts":167,"geoPoint":170},"St. Luke's Clinic - Rheumatology - Boise ( Site 5109)","Boise","Idaho","83702-4565",[168],{"name":95,"role":96,"phone":169},"208-706-9088",{"lat":171,"lon":172},43.6135,-116.20345,{"facility":174,"status":8,"city":175,"state":176,"zip":177,"country":92,"contacts":178,"geoPoint":181},"Johns Hopkins Bayview Medical Center - Johns Hopkins Asthma & Allergy Center ( Site 5132)","Baltimore","Maryland","21224",[179],{"name":95,"role":96,"phone":180},"410-550-0579",{"lat":182,"lon":183},39.29038,-76.61219,{"facility":185,"status":8,"city":186,"state":176,"zip":187,"country":92,"contacts":188,"geoPoint":191},"Arthritis and Rheumatism Associates - Rockville ( Site 5127)","Rockville","20850",[189],{"name":95,"role":96,"phone":190},"240-283-2046",{"lat":192,"lon":193},39.084,-77.15276,{"facility":195,"status":8,"city":196,"state":197,"zip":198,"country":92,"contacts":199,"geoPoint":202},"Kansas City Physician Partners ( Site 5119)","Kansas City","Missouri","64111",[200],{"name":95,"role":96,"phone":201},"816-531-0930",{"lat":203,"lon":204},39.09973,-94.57857,{"facility":206,"status":8,"city":207,"state":208,"zip":209,"country":92,"contacts":210,"geoPoint":213},"Physician Research Collaboration, LLC ( Site 5102)","Lincoln","Nebraska","68516",[211],{"name":95,"role":96,"phone":212},"402-420-1212",{"lat":214,"lon":215},40.8,-96.66696,{"facility":217,"status":8,"city":218,"state":219,"zip":220,"country":92,"contacts":221,"geoPoint":224},"Joseph S. and Diane H. Steinberg Ambulatory Care Center ( Site 5106)","Brooklyn","New York","11201",[222],{"name":95,"role":96,"phone":223},"929-455-2500",{"lat":225,"lon":226},40.6501,-73.94958,{"facility":228,"status":8,"city":229,"state":230,"zip":231,"country":92,"contacts":232,"geoPoint":235},"Joint and Muscle Research Institute ( Site 5108)","Charlotte","North Carolina","28204",[233],{"name":95,"role":96,"phone":234},"704-248-8577",{"lat":236,"lon":237},35.22709,-80.84313,{"facility":239,"status":8,"city":240,"state":241,"zip":242,"country":92,"contacts":243,"geoPoint":246},"Altoona Center for Clinical Research ( Site 5110)","Duncansville","Pennsylvania","16635",[244],{"name":95,"role":96,"phone":245},"814-693-0300",{"lat":247,"lon":248},40.42341,-78.4339,{"facility":250,"status":8,"city":251,"state":241,"zip":252,"country":92,"contacts":253,"geoPoint":256},"Hospital of the University of Pennsylvania ( Site 5134)","Philadelphia","19104",[254],{"name":95,"role":96,"phone":255},"215-662-2454",{"lat":257,"lon":258},39.95238,-75.16362,{"facility":260,"status":8,"city":261,"state":262,"zip":263,"country":92,"contacts":264,"geoPoint":267},"Articularis Healthcare Group dba: Low Country Rheumatology ( Site 5128)","Summerville","South Carolina","29486",[265],{"name":95,"role":96,"phone":266},"843-572-4840",{"lat":268,"lon":269},33.0185,-80.17565,{"facility":271,"status":8,"city":272,"state":273,"zip":274,"country":92,"contacts":275,"geoPoint":278},"Greater Houston Rheumatology ( Site 5103)","Houston","Texas","77095",[276],{"name":95,"role":96,"phone":277},"832-237-0400",{"lat":279,"lon":280},29.76328,-95.36327,{"facility":282,"status":8,"city":283,"state":284,"zip":285,"country":286,"contacts":287,"geoPoint":290},"Centre Rhumatologie De L'Est ( Site 5201)","Rimouski","Quebec","G5L 8W1","Canada",[288],{"name":95,"role":96,"phone":289},"418 723 2445",{"lat":291,"lon":292},48.44879,-68.52396,{"facility":294,"status":8,"city":295,"state":284,"zip":296,"country":286,"contacts":297,"geoPoint":300},"Centre de Recherche Musculo-Squelettique ( Site 5202)","Trois-Rivières","G9A 3Y2",[298],{"name":95,"role":96,"phone":299},"819-370-1301",{"lat":301,"lon":302},46.34515,-72.5477,{"facility":304,"status":8,"city":305,"state":306,"zip":307,"country":308,"contacts":309,"geoPoint":312},"Centro de Estudios GyC ( Site 8206)","Santiago","Region M. de Santiago","7500504","Chile",[310],{"name":95,"role":96,"phone":311},"+56224374879",{"lat":313,"lon":314},-33.45694,-70.64827,{"facility":316,"status":8,"city":305,"state":306,"zip":317,"country":308,"contacts":318,"geoPoint":321},"Enroll SpA ( Site 8203)","7500587",[319],{"name":95,"role":96,"phone":320},"+56940608037",{"lat":313,"lon":314},{"facility":323,"status":8,"city":305,"state":306,"zip":324,"country":308,"contacts":325,"geoPoint":328},"Clinica Dermacross ( Site 8200)","7640881",[326],{"name":95,"role":96,"phone":327},"56942905714",{"lat":313,"lon":314},{"facility":330,"status":8,"city":305,"state":306,"zip":331,"country":308,"contacts":332,"geoPoint":335},"CECIM ( Site 8205)","8331143",[333],{"name":95,"role":96,"phone":334},"56226965804",{"lat":313,"lon":314},{"facility":337,"status":8,"city":305,"state":306,"zip":338,"country":308,"contacts":339,"geoPoint":342},"Bradfordhill ( Site 8212)","8420383",[340],{"name":95,"role":96,"phone":341},"56229490970",{"lat":313,"lon":314},{"facility":344,"status":8,"city":305,"state":306,"zip":338,"country":308,"contacts":345,"geoPoint":348},"Centro Internacional de Estudios Clinicos (CIEC) ( Site 8201)",[346],{"name":95,"role":96,"phone":347},"56227357954",{"lat":313,"lon":314},{"facility":350,"status":8,"city":351,"state":352,"zip":353,"country":354,"contacts":355,"geoPoint":358},"Clinica de la Costa S.A.S. ( Site 8301)","Barranquilla","Atlántico","080020","Colombia",[356],{"name":95,"role":96,"phone":357},"+573017898697",{"lat":359,"lon":360},10.96854,-74.78132,{"facility":362,"status":8,"city":363,"state":364,"zip":365,"country":354,"contacts":366},"Centro de investigacion en reumatologia y especialidades medicas SAS (CIREEM SAS) ( Site 8306)","Bogota","Cundinamarca","110221",[367],{"name":95,"role":96,"phone":368},"+576014853675",{"facility":370,"status":8,"city":371,"state":372,"zip":373,"country":354,"contacts":374,"geoPoint":377},"Fundación Valle del Lili ( Site 8302)","Cali","Valle del Cauca Department","760032",[375],{"name":95,"role":96,"phone":376},"+576023319090",{"lat":378,"lon":379},3.43054,-76.5199,{"facility":381,"status":8,"city":382,"state":383,"zip":384,"country":385,"contacts":386,"geoPoint":389},"Rheuma-Research Lausitz ( Site 6409)","Cottbus","Brandenburg","03042","Germany",[387],{"name":95,"role":96,"phone":388},"+4935575578825",{"lat":390,"lon":391},51.75769,14.32888,{"facility":393,"status":8,"city":394,"state":395,"zip":396,"country":385,"contacts":397,"geoPoint":400},"Rheumazentrum Ruhrgebiet ( Site 6400)","Herne","North Rhine-Westphalia","44649",[398],{"name":95,"role":96,"phone":399},"+4923255920",{"lat":401,"lon":402},51.5388,7.22572,{"facility":404,"status":8,"city":405,"zip":406,"country":385,"contacts":407,"geoPoint":410},"Rheumatologische Schwerpunktpraxis ( Site 6405)","Berlin","10777",[408],{"name":95,"role":96,"phone":409},"+493085993390",{"lat":411,"lon":412},52.52437,13.41053,{"facility":414,"status":8,"city":415,"zip":416,"country":385,"contacts":417,"geoPoint":420},"HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg G ( Site 6404)","Hamburg","20095",[418],{"name":95,"role":96,"phone":419},"+4940323103166",{"lat":421,"lon":422},53.55073,9.99302,{"facility":424,"status":8,"city":425,"state":426,"zip":427,"country":428,"contacts":429,"geoPoint":432},"MICS Centrum Medyczne Bydgoszcz ( Site 6907)","Bydgoszcz","Kuyavian-Pomeranian Voivodeship","85-065","Poland",[430],{"name":95,"role":96,"phone":431},"+48523401414",{"lat":433,"lon":434},53.1235,18.00762,{"facility":436,"status":8,"city":425,"state":426,"zip":437,"country":428,"contacts":438,"geoPoint":441},"Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy ( Site 6904)","85-168",[439],{"name":95,"role":96,"phone":440},"+48523655531",{"lat":433,"lon":434},{"facility":443,"status":8,"city":444,"state":426,"zip":445,"country":428,"contacts":446,"geoPoint":449},"MICS Centrum Medyczne Torun ( Site 6903)","Torun","87-100",[447],{"name":95,"role":96,"phone":448},"+48563004300",{"lat":450,"lon":451},53.01375,18.59814,{"facility":453,"status":8,"city":454,"state":455,"zip":456,"country":428,"contacts":457},"Zespół Poradni Specjalistycznych Reumed Filia nr 1 Wallenroda ( Site 6901)","Lublin","Lubusz Voivodeship","20-607",[458],{"name":95,"role":96,"phone":459},"+48815243333",{"facility":461,"status":8,"city":462,"state":463,"zip":464,"country":428,"contacts":465,"geoPoint":468},"MICS Centrum Medyczne Warszawa ( Site 6905)","Warsaw","Masovian Voivodeship","00-874",[466],{"name":95,"role":96,"phone":467},"+48226291354",{"lat":469,"lon":470},52.22977,21.01178,{"facility":472,"status":8,"city":462,"state":463,"zip":473,"country":428,"contacts":474,"geoPoint":477},"Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im.Prof. El. Reicher-ul.Spartanska 1 ( Site 6906)","02-637",[475],{"name":95,"role":96,"phone":476},"+48226880630",{"lat":469,"lon":470},{"facility":479,"status":8,"city":480,"state":481,"zip":482,"country":483,"contacts":484,"geoPoint":487},"CHUS - Hospital Clinico Universitario ( Site 7102)","Santiago de Compostela","La Coruna","15706","Spain",[485],{"name":95,"role":96,"phone":486},"+34981951036",{"lat":488,"lon":489},42.88052,-8.54569,{"facility":491,"status":8,"city":492,"zip":493,"country":483,"contacts":494,"geoPoint":497},"Hospital Vall d' Hebron ( Site 7101)","Barcelona","08029",[495],{"name":95,"role":96,"phone":496},"+34932746000ext6604",{"lat":498,"lon":499},41.38879,2.15899,{"facility":501,"status":8,"city":502,"zip":503,"country":483,"contacts":504,"geoPoint":506},"Hospital Viamed Santa Elena ( Site 7105)","Madrid","28003",[505],{"name":95,"role":96,"phone":486},{"lat":507,"lon":508},40.4165,-3.70256,{"facility":510,"status":8,"city":511,"zip":512,"country":483,"contacts":513,"geoPoint":516},"Hospital Universitario la Fe ( Site 7107)","Valencia","46026",[514],{"name":95,"role":96,"phone":515},"+34961245869",{"lat":517,"lon":518},39.47391,-0.37966,{"facility":520,"status":8,"city":521,"state":522,"zip":523,"country":524,"contacts":525},"Kyiv Railway Clinical Hospital No.2 of Branch Health Center of the Public Joint Stock Company Ukrain ( Site 7401)","Kiev","Kyiv Oblast","03049","Ukraine",[526],{"name":95,"role":96,"phone":527},"+380505868014",{"facility":529,"status":8,"city":530,"state":531,"zip":532,"country":524,"contacts":533,"geoPoint":536},"Edelweiss Medics ( Site 7409)","Kyiv","Kyivska Oblast","02002",[534],{"name":95,"role":96,"phone":535},"+380678028155",{"lat":537,"lon":538},50.45466,30.5238,{"facility":540,"status":8,"city":530,"state":531,"zip":541,"country":524,"contacts":542,"geoPoint":545},"Medical Center of Limited Liability Company \"Medical Center \"Consilium Medical\" ( Site 7415)","04050",[543],{"name":95,"role":96,"phone":544},"+38 097 769 43 82",{"lat":537,"lon":538},{"facility":547,"status":8,"city":548,"state":549,"zip":550,"country":524,"contacts":551,"geoPoint":554},"Lviv Clin Hospital of Planned Treatment Rehabilitation Palliative Care ( Site 7410)","Lviv","Lviv Oblast","79011",[552],{"name":95,"role":96,"phone":553},"+38 067 379 80 01",{"lat":555,"lon":556},49.83826,24.02324,{"facility":558,"status":8,"city":559,"state":560,"zip":561,"country":524,"contacts":562,"geoPoint":565},"Limited liability company \"Medical center Health Clinic\" ( Site 7412)","Vinnytsia","Vinnytsia Oblast","21009",[563],{"name":95,"role":96,"phone":564},"+38 050 011 53 83",{"lat":566,"lon":567},49.2322,28.46871,{"facility":569,"status":8,"city":559,"state":560,"zip":570,"country":524,"contacts":571,"geoPoint":574},"Municipal Nonprofit Enterprise \"Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 7400)","21028",[572],{"name":95,"role":96,"phone":573},"+380674949895",{"lat":566,"lon":567},{"facility":576,"status":8,"city":530,"zip":577,"country":524,"contacts":578,"geoPoint":581},"Medical Center \"Universal Clinic \"Oberig\" of Limited Liability Company \"Kapytal\" ( Site 7406)","03057",[579],{"name":95,"role":96,"phone":580},"+380672933485",{"lat":537,"lon":538},[583],{"name":584,"role":96,"phone":585,"email":586},"Toll Free Number","1-888-577-8839","Trialsites@msd.com",[588],{"name":589,"affiliation":13,"role":590},"Medical Director","STUDY_DIRECTOR",[],[593],{"label":594,"url":595},"Merck Clinical Trials Information","https:\u002F\u002Fwww.merckclinicaltrials.com",{"nct_id":4,"conditions":597,"biomarkers":598},[19],[],{"nct_id":4,"found":15,"summary":600,"prompt_version":610},{"design":601,"status":602,"heading":603,"summary":604,"follow_up":605,"word_count":606,"commitments":607,"compensation":608,"drugs_mentioned":609},"This is an interventional study with an estimated 140 participants. It includes a 16-week placebo-controlled period.","completed","Study of Tulisokibart for Psoriatic Arthritis","Researchers are studying a new medicine called tulisokibart to see if it can help adults with active Psoriatic Arthritis (PsA). This study will compare tulisokibart to a placebo, which looks like the study medicine but has no active drug. The goal is to find out if tulisokibart can reduce PsA symptoms and if it is safe and well-tolerated. You may be able to join if you are between 18 and 80 years old, have had PsA for at least six months, and also have active plaque psoriasis or a history of it. The main way researchers will measure success is by looking at the percentage of participants who show a 20% improvement in their PsA symptoms after 16 weeks. The current status of this study is unclear.","Participants will be followed for at least 16 weeks to assess the primary endpoint. There is also a long-term extension period of 112 weeks.",127,"Participants will receive either tulisokibart or a placebo through subcutaneous injections. The study involves a 16-week placebo-controlled period, followed by a long-term extension of 112 weeks.","Not stated in the trial record.",[31,41],null]